Hope Biosciences has reportedly received FDA authorization to conduct a pediatric clinical trial using their adipose(fat)-derived mesenchymal stem cells (HB-adMSCs) to assess their impact on juvenile idiopathic arthritis (JIA) in children aged 2 to 16. This trial aims to determine whether intravenous (IV) infusion of these stem cells can alleviate symptoms and enhance the quality … Continue reading Hope Biosciences launches stem cell trial for children with arthritis (Juvenile Rheumatoid/Idiopathic Arthritis)